Furthermore, a recent study in 94 HER2-positive luminal B breast cancer patients showed that, although 13.5% of cases had a germline mutation (V384D) in the MLH1 gene, only 3 cases (3.2%) were MLH1-deficient by IHC [37]. This evidence concerns the gene ERBB2 and breast carcinoma.